Spektron’s first compound, designed through our Q-MAP™ has been synthesized by one of our trusted CRO partners. This compound SPK003583 was designed based on bispecific targeting with de-risking models extending to the human endpoint. That’s to say that we modeled on data from Clinical Trials and used that information to create a novel molecule library (enriched by that data) and screened it – all in silico – to find a set of candidates that were correctly profiled for efficacy, toxicity, and physiochemical properties.
This first compound has been forwarded for an initial round of assays with one of our other trust CRO partners. This is part of our Design-Make-Test cycle and a crucial step in substantiating and improving the platform.